Literature DB >> 34284573

Coordination Compounds As Multi-Delivery Systems for Osteoporosis.

Jéssica S Barbosa1,2, Miguel Pinto3, Sandra Barreiro4, Carlos Fernandes3, Ricardo F Mendes1, Pedro Lavrador1, Vítor M Gaspar1, João F Mano1, Fernanda Borges3, Fernando Remião4, Susana S Braga2, Filipe A Almeida Paz1.   

Abstract

Osteoporosis therapies leveraging bisphosphonates and mineral components (e.g., magnesium, calcium, and strontium) have been raising attention because of their potential for managing this ever-growing disease. The administration of multicomponent therapeutics (combined therapy) in elderly patients is complex and suffers from low patient adherence. Herein, we report an all-in-one combination of four antiosteoporotic components into a new family of coordination complexes: [M2(H4alen)4(H2O)2]·1.5H2O [where M2+ = Mg2+ (1), (Mg0.535Ca0.465)2+ (2) and (Mg0.505Ca0.450Sr0.045)2+ (3)]. These solid-state complexes were prepared, for the first time, through microwave-assisted synthesis. It is demonstrated that the compounds are capable of releasing their antiosteoporotic components, both in conditions that mimic the path along the gastrointestinal tract and in long periods under physiological conditions (pH ∼7.4). More importantly, when administered in low concentrations, the compounds did not elicit a cytotoxic effect toward liver, kidney, and osteoblast-like cell lines. Besides, it is important to highlight the unique coordination complex with four bone therapeutic components, [(Mg0.505Ca0.450Sr0.045)2(H4alen)4(H2O)2]·1.5H2O (3), which significantly promoted osteoblast metabolic activity up to ca. 1.4-fold versus the control group. These findings bring this type of compounds one-step closer to be considered as an all-in-one and more effective treatment for managing chronic bone diseases, prompting further research on their therapeutic properties.

Entities:  

Keywords:  bisphosphonates; controlled release; coordination compounds; osteoporosis; toxicological safety

Year:  2021        PMID: 34284573     DOI: 10.1021/acsami.1c09121

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  4 in total

1.  Gut Metabolite Urolithin A Inhibits Osteoclastogenesis and Senile Osteoporosis by Enhancing the Autophagy Capacity of Bone Marrow Macrophages.

Authors:  Huaqiang Tao; Yunxia Tao; Chen Yang; Wenming Li; Wei Zhang; Xueyan Li; Ye Gu; Yujing Hong; Huilin Yang; Yu Liu; Xing Yang; Dechun Geng
Journal:  Front Pharmacol       Date:  2022-05-12       Impact factor: 5.988

2.  Exploiting the Multifunctionality of M2+/Imidazole-Etidronates for Proton Conductivity (Zn2+) and Electrocatalysis (Co2+, Ni2+) toward the HER, OER, and ORR.

Authors:  Álvaro Vílchez-Cózar; Eirini Armakola; Maria Gjika; Aurelia Visa; Montse Bazaga-García; Pascual Olivera-Pastor; Duane Choquesillo-Lazarte; David Marrero-López; Aurelio Cabeza; Rosario M P Colodrero; Konstantinos D Demadis
Journal:  ACS Appl Mater Interfaces       Date:  2022-02-22       Impact factor: 9.229

3.  Effects of Bisphosphonate on Osteocyte Proliferation and Bone Formation in Patients with Diabetic Osteoporosis.

Authors:  Beifang Weng; Chunhua Chen
Journal:  Comput Math Methods Med       Date:  2022-07-06       Impact factor: 2.809

4.  Drug-Inclusive Inorganic-Organic Hybrid Systems for the Controlled Release of the Osteoporosis Drug Zoledronate.

Authors:  Maria Vassaki; Savvina Lazarou; Petri Turhanen; Duane Choquesillo-Lazarte; Konstantinos D Demadis
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.